Sunstone Life Science Ventures
DenmarkKey facts
Recent exits
No exits recorded yet.
Coverage notes
0 funds tracked, 0 portfolio companies (0 active · 0 realized). Verified weekly from public filings and deal announcements.
About Sunstone Life Science Ventures
Sunstone Life Science Ventures is a pure-play Nordic life sciences venture capital firm with €500 million of cumulative assets across four funds as of December 2024 (Fund I €200 million 2007, Fund II €86 million 2007, Fund III €80 million 2012, Fund IV €92 million 2019), headquartered in Copenhagen at Frederiksberg. The firm was founded in 2007 as a spin-out from the broader Sunstone Capital platform, supported by InnovFin Equity under Horizon 2020 and EFSI. Sunstone Life Science Ventures has built 44 portfolio exits historically.
Investment thesis
Sunstone Life Science Ventures deploys capital through four life sciences funds (Fund I through IV), targeting early-stage life sciences therapeutics investments at preclinical to clinical-stage biotech with clear M&A or IPO exit paths. Sector focus spans biotechnology, therapeutics, pharmaceuticals, drug discovery, rare diseases and oncology. Geographic deployment is anchored in Nordic and broader European focus with selective US co-investments. The M&A-led exit strategy aligns with global pharma demand for late-preclinical and clinical assets.
Recent activity
Recent realised exits include medical devices (2024) and biotech (2024). Recent acquisitions include TargED Biopharmaceuticals (drug discovery, December 2025) and DiogenX Series A (biotech, 2024). The platform continues active deployment of Fund IV across the European life sciences ecosystem. Detailed buyer names and multiple data available on Pro at €49/month.
Similar firms
Other private equity firms tracked on GP Intel.
See the full fund history.
Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.
Already a member? Sign in